Ann Hunter-Van Kirk

What are your strategies to optimize capital here and views on sort of the current M&A market and where you go next from here?

Fantastic.

And what are your thoughts for next steps for the company?

Fantastic.

Richard, thank you so much for joining us today on Bloomberg Intelligence's Vanguards of Healthcare podcast.

I'm Anne Hunter-Van Kirk, Senior Biopharmaceuticals Analyst here, and we are so pleased to have spoken with Richard Lowenthal, CEO of ARS Pharmaceuticals.

Thanks again.